Immunic AG
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020
DGAP-News: Immunic, Inc.
/ Key word(s): Study results/Conference
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020 – Live Webcast to be Held From 9:00 am to 1:00 pm ET – NEW YORK, May 19, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day today, May 19, 2020, from 9:00 am to 1:00 pm ET. Immunic’s management and invited key opinion leaders, specializing in multiple sclerosis and inflammatory bowel disease, will discuss today’s treatment options for, and the unmet medical needs of, chronic inflammatory and autoimmune diseases, as well as clinical progress of Immunic’s selective oral immunology programs and their potential advantages over the current treatment landscape. Management will also discuss the company’s coronavirus disease 2019 (COVID-19) program. During the event, Immunic will provide recently obtained preclinical data testing the company’s lead asset, IMU-838, a selective oral DHODH inhibitor, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), showing that, in in vitro models, IMU-838 is able to inhibit replication of clinical isolates of SARS-CoV-2, obtained from patients with COVID-19, at drug concentrations consistent with previously employed IMU-838 dosing regimens. Highlights will include: – Validation of previously published antiviral data against SARS-CoV-2 in monkey Vero cells showing antiviral activity with EC90 of 7 µM – Determination of strong antiviral activity in human lung epithelial cells infected with SARS-CoV-2 clinical isolates, achieving a virus reduction of 3-log units with 10 µM of IMU-838; EC50 concentrations are ranging between 1 and 6 µM in various assay systems – Review of previously published IMU-838 pharmacokinetic data, showing that in earlier trials, steady state concentrations of 10-30 µM were reached, and that these dosing regimens have been associated with favorable safety and tolerability profiles in prior clinical data sets – Insights into the anticipated multifold antiviral mode of action of IMU-838 by inhibiting viral replication, inducing innate immunity and dampening the excessive immune response thought to be associated with cytokine storm – Data showing IMU-838’s broad-spectrum antiviral activity in vitro for HIV, HCV, hCMV and the Arenavirus causing Lassa fever Immunic will also present preclinical mode of action and first pharmacokinetic data from the current, single ascending dose part in healthy volunteers of the ongoing phase 1 trial of IMU-935, a potentially best-in-class RORγt inverse agonist. Highlights will include: – How IMU-935 improves the balance between regulatory T cells and Th17 cells, and how it shows selectivity towards IL-17 cytokines and Th17 cells over other cellular effects – Data from the first four cohorts of the ongoing and still blinded clinical phase 1 single ascending dose part of the study, demonstrating dose linear pharmacokinetics and a benign safety profile The full data sets will be publicly disclosed in a Current Report on Form 8-K. Webcast Details – Dr. Daniel Vitt, Chief Executive Officer and President – Dr. Andreas Muehler, Chief Medical Officer – Dr. Hella Kohlhof, Chief Scientific Officer – Dr. Manfred Groeppel, Chief Operating Officer Featured key opinion leaders will be: – For multiple sclerosis: Robert Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio – For inflammatory bowel disease: Jean-Frederic Colombel, MD, Professor of Medicine, Director of The Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Director of The Leona M. and Harry B. Helmsley Inflammatory Bowel Disease Center, Icahn School of Medicine, Mount Sinai Hospital, New York Agenda (Eastern time, times are estimates): – 09:00 – 09:10 Welcome and Company Introduction – 09:10 – 09:30 Introduction to Lead Asset IMU-838 – 09:30 – 10:00 IMU-838 as a Potential Treatment Option for COVID-19 – 10:00 – 10:40 Multiple sclerosis: Robert Fox, MD – 10:40 – 11:15 Clinical Development Program for IMU-838 – 11:15 – 11:25 Introduction to IMU-935 – 11:25 – 11:40 Positioning of IMU-935 and Ongoing Phase 1 Program – 11:40 – 11:50 Introduction to IMU-856 – 11:50 – 12:30 Inflammatory Bowel Disease: Jean-Frederic Colombel, MD – 12:30 – 12:45 Positioning of IMU-856 and Clinical Planning – 12:45 – 01:00 Summary and Closing Remarks To participate in the live webcast, please follow this link: The webcast will be held in English. Questions can be asked via the question and answer tool any time during the presentation. An archived replay of the webcast will be available on Immunic’s website at: ir.imux.com. About Immunic, Inc. Cautionary Statement Regarding Forward-Looking Statements Contact Information US IR Contact US Media Contact
19.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |